Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

The approval of a new drug for cancer treatment by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is based on positive, well-designed randomized phase III clinical trials (RCTs). However, not all of them are analyzed to support the recommendations. For this reason,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Adela, Esposito, Francis, Oliveres, Helena, Torres, Ferran, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918206/
https://www.ncbi.nlm.nih.gov/pubmed/33668473
http://dx.doi.org/10.3390/jcm10040746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918206/
https://www.ncbi.nlm.nih.gov/pubmed/33668473
http://dx.doi.org/10.3390/jcm10040746

Ejemplares similares